Free Trial

Cellectar Biosciences (CLRB) Competitors

Cellectar Biosciences logo
$4.80 -0.06 (-1.13%)
As of 01:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CLRB vs. LVTX, ATHE, TELO, RNTX, KALA, LTRN, KZR, OKUR, ESLA, and BDRX

Should you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include LAVA Therapeutics (LVTX), Alterity Therapeutics (ATHE), Telomir Pharmaceuticals (TELO), Rein Therapeutics (RNTX), KALA BIO (KALA), Lantern Pharma (LTRN), Kezar Life Sciences (KZR), OnKure Therapeutics (OKUR), Estrella Immunopharma (ESLA), and Biodexa Pharmaceuticals (BDRX). These companies are all part of the "pharmaceutical products" industry.

Cellectar Biosciences vs. Its Competitors

Cellectar Biosciences (NASDAQ:CLRB) and LAVA Therapeutics (NASDAQ:LVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

LAVA Therapeutics has higher revenue and earnings than Cellectar Biosciences. LAVA Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectar BiosciencesN/AN/A-$44.58M-$21.92-0.22
LAVA Therapeutics$11.98M3.01-$25.11M-$1.04-1.32

Cellectar Biosciences presently has a consensus price target of $375.00, indicating a potential upside of 7,720.65%. LAVA Therapeutics has a consensus price target of $3.17, indicating a potential upside of 131.14%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than LAVA Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectar Biosciences
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
LAVA Therapeutics
0 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

LAVA Therapeutics' return on equity of -86.38% beat Cellectar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cellectar BiosciencesN/A -619.70% -158.04%
LAVA Therapeutics N/A -86.38%-34.12%

In the previous week, Cellectar Biosciences had 3 more articles in the media than LAVA Therapeutics. MarketBeat recorded 3 mentions for Cellectar Biosciences and 0 mentions for LAVA Therapeutics. Cellectar Biosciences' average media sentiment score of 0.49 beat LAVA Therapeutics' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Cellectar Biosciences Neutral
LAVA Therapeutics Neutral

Cellectar Biosciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.

16.4% of Cellectar Biosciences shares are held by institutional investors. 5.0% of Cellectar Biosciences shares are held by company insiders. Comparatively, 9.5% of LAVA Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cellectar Biosciences beats LAVA Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Cellectar Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLRB vs. The Competition

MetricCellectar BiosciencesMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$8.68M$10.54B$5.58B$9.01B
Dividend YieldN/A2.09%5.25%4.03%
P/E Ratio-0.2216.5727.5120.20
Price / SalesN/A31.18415.84172.51
Price / CashN/A22.7937.0657.97
Price / Book0.533.748.085.61
Net Income-$44.58M$235.43M$3.17B$248.50M
7 Day Performance-0.54%4.63%3.57%4.92%
1 Month Performance-56.32%4.95%3.74%7.42%
1 Year Performance-93.20%-10.05%33.78%21.48%

Cellectar Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLRB
Cellectar Biosciences
3.2881 of 5 stars
$4.80
-1.1%
$375.00
+7,720.6%
-93.3%$8.68MN/A-0.2210
LVTX
LAVA Therapeutics
1.8205 of 5 stars
$1.32
flat
$3.17
+139.9%
-28.0%$34.72M$4.99M-1.2760Positive News
ATHE
Alterity Therapeutics
2.6435 of 5 stars
$3.87
-6.7%
$12.00
+210.1%
+108.0%$34.32MN/A0.0010Gap Down
TELO
Telomir Pharmaceuticals
2.3791 of 5 stars
$1.15
flat
$15.00
+1,204.3%
-72.7%$34.22MN/A-2.741
RNTX
Rein Therapeutics
N/A$1.54
+2.0%
N/AN/A$34.12MN/A-0.549
KALA
KALA BIO
3.6828 of 5 stars
$5.28
+3.5%
$13.50
+155.7%
-11.4%$34.06M$3.89M-0.6430News Coverage
Gap Up
LTRN
Lantern Pharma
2.4962 of 5 stars
$3.15
-3.1%
$25.00
+693.7%
-20.8%$33.96MN/A-1.7120News Coverage
Positive News
High Trading Volume
KZR
Kezar Life Sciences
4.1665 of 5 stars
$4.55
-0.7%
$39.50
+768.1%
-18.9%$33.26M$7M-0.4260Negative News
OKUR
OnKure Therapeutics
2.8673 of 5 stars
$2.39
+0.4%
$32.33
+1,252.9%
N/A$32.29MN/A-0.45N/A
ESLA
Estrella Immunopharma
2.239 of 5 stars
$0.88
+0.2%
$16.00
+1,714.7%
-22.1%$31.89MN/A-3.39N/AGap Up
BDRX
Biodexa Pharmaceuticals
N/A$0.87
+0.8%
N/AN/A$31.63MN/A0.0020Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:CLRB) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners